AusperBio Secures RMB 100 Million in Pre-A+ Financing to Advance Development of Novel Oligonucleotide Therapeutics

On November 1, 2023, AusperBio (Ausper Biopharma Co., Ltd. and AusperBio Therapeutics, Inc.) announced the completion of a Pre-A+ round of financing worth 100 million RMB. This round of financing was led by follow-on investments from the Pre-A round investors.The funds were completed in the middle of this year.This financing will help accelerate the advancement of AusperBio's global clinical trials for AHB-137 and the research and development of other targeted delivery Med-Oligo™ small nucleic acid innovative drugs.

AHB-137, a naked antisense oligonucleotide (ASO) with the potential to become a cornerstone for the functional cure of chronic hepatitis B, is the first innovative drug from AusperBio's self-developed Med-Oligo™ platform to enter clinical trials. Its excellent preclinical data garnered significant attention at the 2023 EASL™ conference. Currently, AHB-137 is undergoing clinical trials simultaneously in multiple countries and regions, including New Zealand, China, and the United States. Through global strategic planning, it aims to accelerate the goal of achieving a functional cure for hepatitis B.

Founder & CEO of AusperBio, Dr. Guozheng ChengRepresentation: "Thank you to AusperBio's investors for their continued support and recognition. This Pre-A+ round of investment coincides with the efficient development of AHB-137’s global clinical trials, and the swift completion of this financing round enables the AusperBio team to...AggregationResources. This will enable the simultaneous conduct of clinical trials for AHB-137 in China, the United States, and other countries and regions, accelerating the study of its efficacy in patients with chronic hepatitis B. Additionally, this round of financing will greatly expediteThe innovative breakthrough of the Med-Oligo™ small nucleic acid drug platform technology achieves more efficient intrahepatic and extrahepatic targeted therapies, meeting the needs.Broader and Unresolved"Clinical needs."